What did @jddenhamfit actually say?
The short version: a fitness creator with a history of four back surgeries says BPC-157, TB-500, and a product called "the glow" dropped their sciatic pain by "90 to 95%" in roughly a week of high-dose use. They took these peptides morning, night, and mid-day during a flare. The recommendation is direct: "you can take huge quantities of these peptides. They are going to heal your injuries." That last sentence is the part worth examining closely, because it slides from personal anecdote into a universal promise.
To be fair about the setup: the creator is describing real symptoms. Sciatica following multiple spinal surgeries is a legitimate and often brutal condition. The frustration behind this video is credible. What's less credible is the leap from "this helped me this week" to "it will really help. I promise."
Does the science back this up?
The honest answer is: partially, in animal models, and barely in humans. BPC-157 has the stronger preclinical record of the two. Studies in rodents show it can accelerate tendon healing, reduce inflammation, and modulate dopamine and serotonin pathways involved in pain perception (Sikiric et al., 2018, Current Pharmaceutical Design). TB-500, a synthetic fragment of Thymosin Beta-4, has shown tissue repair effects in animal wound healing studies (Philp et al., 2004, Journal of Cell Science).
Here is the problem: neither peptide has completed a randomized controlled trial in humans for sciatica or nerve pain. The mechanistic plausibility is there. The clinical evidence in people is not. The National Institutes of Health has no registered completed trials on BPC-157 for spinal pain. What we have is animal data, anecdote, and a growing community of self-experimenters reporting results that may reflect the placebo effect, natural resolution of a flare, or, in some cases, genuine benefit we cannot yet measure properly.
What did they get wrong (or right)?
They got the basic biochemistry roughly right: peptides are chains of amino acids, and both BPC-157 and TB-500 are studied for tissue repair signaling. That framing is not inaccurate. Credit where it is due.
What they got wrong is the certainty. Saying these peptides "are going to heal your injuries" and "I promise" converts an anecdote into a guarantee. Sciatica from post-surgical scar tissue or nerve impingement can fluctuate dramatically on its own. A 95% improvement in one week could be the peptides. It could also be the natural arc of a flare resolving, a change in activity, or any number of uncontrolled variables. The creator has no way to isolate the cause, and neither do we.
The dosing advice is also a problem. Recommending "huge doses" and "large quantities" to a general audience, without any reference to individual health status, other medications, or clinical supervision, is not responsible guidance. GHK-Cu, present in "the glow," has its own separate mechanistic profile and stacking all three without clinical context adds compounding unknowns.
What should you actually know?
BPC-157 and TB-500 are not FDA-approved for any indication. They are available in the US primarily through compounding pharmacies or research chemical suppliers, and their regulatory status is actively shifting. The FDA has flagged BPC-157 as a substance of concern in compounded preparations. That does not make them automatically dangerous, but it does mean quality control, dosing standards, and long-term safety data are all genuinely uncertain.
If you have sciatica, especially post-surgical sciatica, the evidence-based options with actual human trial data include physical therapy, epidural steroid injections for acute flares, and in some cases surgical revision. Those are not as exciting to post about. Peptide therapy may eventually earn a place in that list, but it is not there yet based on current published evidence.
A telehealth provider who prescribes peptides responsibly will take your history, review your imaging, and not tell you to take "huge doses" because a fitness creator had a good week.